Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin

Université NAZI BONI

Status and phase: Completed; Phase 4

Conditions: Type 1 Diabetes

Treatments: Drug: Humulin N plus Humulin R; Drug: premix insulin human isophane suspension and insulin human

Study type: Interventional

Funder types: Other

Identifiers

NCT05768191

2023-SOMIBF-01

Details and patient eligibility

About

The goal of this clinical trial is to compare glycemic control and variability between children and adolescents with type 1 diabetes treated by a two daily injection of premixed human insulin (Humulin 30/70) and those who have a basal bolus scheme (Humulin N + Humulin R) in a resources limited setting.

The main question it aims to answer is: what is the effectiveness of premixed human insulin on glycemic control? Ten participants will be randomized initially to premix insulin human isophane suspension and insulin human injection (Humulin 30/70) twice daily, and 10 persons to insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals. At the end of the initial 16-wk treatment (period 1), all patients will be crossed over to the alternate treatment arm for an additional 16 wk (period 2). Insulin doses will be adjusted weekly by the clinical site according to a prespecified insulin intensification algorithm to achieve target fasting [<110 mg/dl (6.1 mmol/liter)], bedtime [<130 mg/dl (7.2 mmol/liter)], and premeal [<110 mg/dl (6.1 mmol/liter)] glucose levels until HbA1c was below 7.0%.

Subjects will receive training on the FreeStyle Libre CGMS System, electronic hand-held personal digital assistant (e-diary), and self-monitoring of blood glucose (SMBG), including recording glucose, insulin doses, and symptoms of hypo- or hyperglycemia.

Enrollment: 22 patients

Sex: All

Ages: 5 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female 5 - 18 years of age
• Be diagnosed for at least 1 year at the date of inclusion.
• Have been regular at consultations during the last 12 years preceding inclusion (at least 3 visits)
• Willing and able to inject insulin human isophane and multi-day dosing of rapid acting human insulin.
• Willing and able to perform self-monitoring of blood glucose (SMBG) four times a day and continuous glucose monitoring (CGMS) for 48 hours at three time periods during the study
• Have (patient or guardian) a minimum 4 years primary school level
• Have (patient or guardian) a connected cellphone that can install the free FreeStyle link application and use connected messaging app

Exclusion criteria

• pregnant or lactating females
• opposition to participating in the study
• residing outside the towns where the care centers are located
• Any disease or condition (including abuse of illicit drugs, prescription medicines or alcohol) that in the opinion of the investigator or sponsor may interfere with the study compliance and completion of the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

22 participants in 2 patient groups

Humulin N plus Humulin R

Active Comparator group

Description:

10 subjects will receive insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals

Treatment:

Drug: Humulin N plus Humulin R

Premix human isophane suspension plus insulin human injection

Experimental group

Description:

10 subjects will receive premix insulin human isophane suspension and insulin human injection twice daily

Treatment:

Drug: premix insulin human isophane suspension and insulin human